TY - JOUR
T1 - Theranostics and metabolotheranostics for precision medicine in oncology
AU - Bhujwalla, Zaver M.
AU - Kakkad, Samata
AU - Chen, Zhihang
AU - Jin, Jiefu
AU - Hapuarachchige, Sudath
AU - Artemov, Dmitri
AU - Penet, Marie France
N1 - Funding Information:
Support from NIH R01 CA82337, R01 CA136576, R01 CA193365 and R35 CA209960 is gratefully acknowledged. We gratefully acknowledge Dr. Ackerman’s kind support and valuable discussions over the past decade.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/6
Y1 - 2018/6
N2 - Most diseases, especially cancer, would significantly benefit from precision medicine where treatment is shaped for the individual. The concept of theragnostics or theranostics emerged around 2002 to describe the incorporation of diagnostic assays into the selection of therapy for this purpose. Increasingly, theranostics has been used for strategies that combine noninvasive imaging-based diagnostics with therapy. Within the past decade theranostic imaging has transformed into a rapidly expanding field that is located at the interface of diagnosis and therapy. A critical need in cancer treatment is to minimize damage to normal tissue. Molecular imaging can be applied to identify targets specific to cancer with imaging, design agents against these targets to visualize their delivery, and monitor response to treatment, with the overall purpose of minimizing collateral damage. Genomic and proteomic profiling can provide an extensive ‘fingerprint’ of each tumor. With this cancer fingerprint, theranostic agents can be designed to personalize treatment for precision medicine of cancer, and minimize damage to normal tissue. Here, for the first time, we have introduced the term ‘metabolotheranostics’ to describe strategies where disease-based alterations in metabolic pathways detected by MRS are specifically targeted with image-guided delivery platforms to achieve disease-specific therapy. The versatility of MRI and MRS in molecular and functional imaging makes these technologies especially important in theranostic MRI and ‘metabolotheranostics’. Our purpose here is to provide insights into the capabilities and applications of this exciting new field in cancer treatment with a focus on MRI and MRS.
AB - Most diseases, especially cancer, would significantly benefit from precision medicine where treatment is shaped for the individual. The concept of theragnostics or theranostics emerged around 2002 to describe the incorporation of diagnostic assays into the selection of therapy for this purpose. Increasingly, theranostics has been used for strategies that combine noninvasive imaging-based diagnostics with therapy. Within the past decade theranostic imaging has transformed into a rapidly expanding field that is located at the interface of diagnosis and therapy. A critical need in cancer treatment is to minimize damage to normal tissue. Molecular imaging can be applied to identify targets specific to cancer with imaging, design agents against these targets to visualize their delivery, and monitor response to treatment, with the overall purpose of minimizing collateral damage. Genomic and proteomic profiling can provide an extensive ‘fingerprint’ of each tumor. With this cancer fingerprint, theranostic agents can be designed to personalize treatment for precision medicine of cancer, and minimize damage to normal tissue. Here, for the first time, we have introduced the term ‘metabolotheranostics’ to describe strategies where disease-based alterations in metabolic pathways detected by MRS are specifically targeted with image-guided delivery platforms to achieve disease-specific therapy. The versatility of MRI and MRS in molecular and functional imaging makes these technologies especially important in theranostic MRI and ‘metabolotheranostics’. Our purpose here is to provide insights into the capabilities and applications of this exciting new field in cancer treatment with a focus on MRI and MRS.
KW - Cancer
KW - Metabolotheranostics
KW - Precision medicine
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85044001124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044001124&partnerID=8YFLogxK
U2 - 10.1016/j.jmr.2018.03.004
DO - 10.1016/j.jmr.2018.03.004
M3 - Article
C2 - 29705040
AN - SCOPUS:85044001124
VL - 291
SP - 141
EP - 151
JO - Journal of Magnetic Resonance
JF - Journal of Magnetic Resonance
SN - 1090-7807
ER -